参考文献/References:
[1]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂,2018,10(1):4-67.
[2]Haluzm M.Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm[J].Vnitr Lek,2017,63(2):87-92.
[3]Di LL,Mangano M,Ronco C,et al.The treatment of type 2 diabetes mellitus in patients with chronic kidney disease：what to expect from new oral hypoglycemic agents[J].Diabetes Metab Syndr,2017(Suppl 1):S295-S305.
[4]Choi CI.Sodium-glucose cotransporter 2(SGLT2)inhibitors from natural products:discovery of next-generation antihyperglycemic agents[J].Molecules,2016,21(9):1136.
[5]胡秀卓,吕莉.钠-葡萄糖共转运体2抑制剂在治疗2型糖尿病中的应用[J].中国临床药理学与治疗学,2015,20(3):338-343.
[6]谷光宇,郑少雄.钠-葡萄糖协同转运蛋白2抑制剂-糖尿病治疗新途径[J].中国实用内科杂志,2014,34(10):962-968.
[7]Mamidi RN,Cuyckens F,Chen J,et al.Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans[J].Drug Metab Dispos,2014,42(5):903-916.
[8]Sha S,Devineni D,Ghosh A,et al.Pharmacodynamic effects of canagliflozin，a sodium glucose co-transporter 2 inhibitor，from a randomized study in patients with type 2 diabetes[J].PLoS One,2014,9(8):e105638.
[9]Whalen K,Miller S,Onge ES.The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes[J].Clin Ther,2015,37(6):1150-1166.
[10]Bode B,Stenl?觟f K,Harris S,et al.Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes[J].Diabetes Obes Metab,2015,17(3):294-303.
[11]Qiu R，Gapuano G，Meininger G.Efficacy and safety of twice-daily treatment with canagliflozin，a sodium glucose co-transporter 2 inhibitor，added on to metformin monotherapy in patients with type 2 diabetes mellitus[J].J Clin Transl End Ocrinol,2014,1(2):54-60.
[12]Inagaki N,Kondo K,Yoshinari T,et al.Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes:a 52-week open-label study[J].J Diabetes Invest,2015,6(2):210-218.
[13]Gilbert RE,Weir MR,Fioretto P,et al.Impact of age and estimated glomerular filtration rate on the glycemic efficacy and safety of canagliflozin:A pooled analysis of clinical studies[J].Can J Diabetes,2016,40(3):247-257.
[14]Neal B,Perkovic V,de Zeeuw D,et al.Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotrans-porter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes[J].Diabetes Care,2015,38(3):403-411.
[15]Yang XP,Lai D,Zhong XY,et al.Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis[J].Eur J Clin Pharmacol,2014,70(10):1149-1158.
[16]Leiter LA,Yoon KH,Arias P,et al.Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study[J].Diabetes Care,2015,38(3):355-364.
[17]Weir MR,Januszewicz A,Gilbert RE,et al.Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus[J].J Clin Hypertens (Greenwich),2014,16(12):875-882.
[18]纪立农,郭立新,郭晓蕙,等.钠-葡萄糖共转运蛋白2(SGLT2)抑制剂临床合理应用中国专家建议[J].中国糖尿病杂志,2016,24(10):865-870.
[19]Nyirjesy P,Sobel JD,Fung A,et al.Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies[J].Curr Med Res Opin,2014,30(6):1109-1119.
[20]邹寿涛.口服降血糖新药-坎格列净[J].中南药学,2014,12(12):1277-1279.
[21]Reilly TP,Graziano MJ,Janovitz EB,et al.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus[J].Diabetes Ther,2014,5(1):73-96.
相似文献/References:
[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in
Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(10):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(10):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的
相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(10):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(10):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(10):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(10):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[7]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(10):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[8]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Journal of Medical Information,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[9]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Journal of Medical Information,2022,35(10):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[10]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行
健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Journal of Medical Information,2018,31(10):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]